Fosun Pharma "long-acting Botox" starts Phase III clinically

From insight database () RT002 (DaxibotulinumtoxinA for injection), Fosun Pharma was authorized by Revance of the United States in December 2018 to use, import, sell and other commercially available (excluding manufacturing) rights in the region (i.e., Chinese mainland, Hong Kong and Macao Special Administrative Regions, the same between 2018, and Revance remains the right to use, import and other commercialization (excluding manufacturing) of the new drug.
the new drug is a biological product intended for: (1) cosmetic adaptations, such as the treatment of moderate to severe eyebrow tattoos, and (2) treatment of adhesive disorders, such as neck dystrophea.
insight database shows that the new drug for moderate to severe eyebrow tattoo therapy is still in the U.S. FDA listing application stage, for neck dystain disorder treatment in the U.S. in Phase III clinical trials.
source: Insight database (currently, there is no Daxibotulinumtoxin A type Botox products on the market, domestic similar products have been listed A Botox including Allergan plc's Botox ® A Botox, Lanzhou Institute of Biological Products limited liability company's strength® treatment with type A botulinum toxin.
2019, according to the latest IQVIA CHPA data, the amount of Botox sold for injection a type A in China was approximately RMB354 million.
previous Revival Pharmaceuticals announcement, the Group's cumulative research and development investment in the new drug at this stage as of May 2020 was approximately RMB211.31 million (unaudited; including licensing fees).